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Recent evidence indicates activated mitogen-activated protein kinase (MAPK) p38 has a critical function in
human cytomegalovirus (HCMV) viral DNA replication in infected human fibroblasts. To elucidate the
mechanism of HCMV-mediated p38 activation, we have performed a detailed analysis of p38 activation and the
kinases associated with this activation at different times postinfection. We demonstrate that p38 kinase activity
is strongly increased following viral infection. Inhibition of this activity significantly inhibited HCMV-induced
hyperphosphorylation of pRb and phosphorylation of heat shock protein 27, suggesting that p38 activation is
involved in virus-mediated changes in host cell metabolism throughout the course of infection. We then provide
evidence that p38 activation is mediated by different mechanisms at early times versus later times of infection.
At early times of infection (8 to 14 h postinfection [hpi]), when p38 activation is first observed, no significant
activation of the three kinases which can directly phosphorylate p38 (namely, MKK3, MKK6, and MKK4) is
detected. Using vectors which express dominant negative proteins, we demonstrate that basal MKK6 kinase
activity is necessary for HCMV-mediated p38 activation at these early times of infection (12 hpi). Then, we use
ATP depletion to show that at 12 hpi, HCMV inhibits dephosphorylation of activated p38. These two experi-
ments suggest that HCMV activates p38 by inhibition of dephosphorylation of p38. In contrast to early times
of infection, at later times of infection (48 to 72 hpi), increased MKK3/6, but not MKK4, activity is observed.
These results indicate that at early times of HCMV infection, increased steady-state levels of activated p38 is
mediated at least in part by inhibition of dephosphorylation of p38, while at later times of infection p38
activation is due to increased activity of the upstream kinases MKK3 and MKK6. These findings indicate that
HCMV has developed multiple mechanisms to ensure activation of the MAPK p38, a kinase critical to viral
infection.
Human cytomegalovirus (HCMV) is a ubiquitous betaher-
pesvirus that is found in over 80% of the population. While
asymptomatic in most immunocompetent hosts, in immuno-
compromised individuals, such as transplant recipients and
AIDS patients, HCMV causes a wide range of clinical symp-
toms which, if left untreated, are often fatal (6, 17). Currently,
patients are treated with antiviral drugs, such as ganciclovir
and Foscarnet, which inhibit HCMV-permissive infection (33,
37, 40). However, with the dramatic rise in immunocompro-
mised individuals who require long-term antiviral treatment,
drug-resistant strains of HCMV are becoming more common,
resulting in a loss of ability to control infection (reviewed in
reference 12). This problem has resulted in the need to identify
and characterize new antiviral targets which can be used to
inhibit the life cycle of HCMV.
Several reports have demonstrated that HCMV infection
induces activation of numerous host cell transcription factors
such as Sp-1, CREB/ATF family members, and NF-kB (7,
20–22, 30, 56–58). This activation ensures high levels of expres-
sion of the many viral and cellular genes which are required for
completion of the lytic life cycle. Since many of these transcrip-
tion factors are required for expression of certain genes, and
hence are necessary for completion of the viral life cycle, in-
hibiting their activation represents one mechanism to inhibit
viral infection.
One way to inhibit the activation of cellular transcription
factors may be to inhibit upstream signaling events which con-
trol their activity. Since the transactivation function of many
cellular transcription factors is at least partially regulated by
phosphorylation events, identifying and inhibiting cellular ki-
nases which phosphorylate transcription factors may represent
one mechanism to inhibit HCMV permissiveness (2, 49). This
has led members of our laboratory and others to search for
specific kinase pathways which are activated following HCMV
infection and which activate transcription factors. Mitogen-
activated protein kinases (MAPKs) are examples of kinases
which activate numerous transcription factors, and some mem-
bers of the MAPK family are strongly activated following
HCMV infection (19, 46).
MAPKs are important cellular signaling kinases which are
activated by dual phosphorylation on specific tyrosine and
threonine residues in response to various external and internal
stimuli (reviewed in references 10 and 45). In mammalian cells,
three general groups of MAPKs have been identified: extra-
cellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-termi-
nal kinase (JNK), and p38/Hog. Each MAPK is positioned at
the bottom of a distinct kinase pathway composed of three
sequential dual-specificity kinases, generically termed the
MAPKKK (MKKK or MEKK), MAPKK (MKK or MEK),
and MAPK. Following stimulation, the MKKK is dually phos-
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phorylated on specific residues by cellular signaling molecules.
This activated MKKK then phosphorylates the MKK. Once
activated, the MKK phosphorylates the MAPK on the appro-
priate threonine and tyrosine residues, resulting in MAPK
activation (10, 45).
Activated MAPKs can phosphorylate numerous substrates,
including a variety of transcription factors (2, 28, 52). In the
case of transcription factors, MAPK-mediated phosphoryla-
tion is a common mechanism utilized by the cell to induce gene
expression (28, 52). Largely through their ability to regulate
transcription factors, MAPKs regulate changes in the cell rang-
ing from cell growth to apoptosis to senescence.
Because of the many effects of MAPK signaling on cell
growth and viability, the level of phosphorylated, and hence
active, MAPK is tightly regulated by the cell. Phosphorylation
of MAPK is determined by two processes, MKK kinase activity
and phosphatase activity. In the absence of stimulation, there
is a low level of basal MKK kinase activity, which phosphory-
lates the MAPK. This basal activity is counteracted by an equal
low level of basal MAPK phosphatase activity. This balance
prevents an accumulation of activated MAPK in the absence of
stimulation. Following stimulation, MAPK is dramatically ac-
tivated (by phosphorylation via the MAPK pathway). In many
instances, shortly after MAPK activation, MAPK phosphatases
are activated. However, the high levels of MKK activity pre-
vents a decrease in the amount of activated MAPK. Once the
upstream signal subsides, MKK activity drops, and the MAPK
is quickly dephosphorylated by the activated phosphatases (re-
viewed in reference 16).
Numerous viruses activate one or more of the MAPKs. For
example, simian virus 40 (SV40) activates ERK1/2, herpes
simplex virus (HSV) activates both JNK and p38, and simian
immunodeficiency virus activates all three MAPKs (34, 42, 54,
59). In addition, MAPK activation can be induced by viral
binding to the host cell, such as is the case with simian immu-
nodeficiency virus activation of ERK1/2, JNK, and p38, or it
can require viral protein synthesis, as is the case with HSV
activation of JNK (42).
While there are many reports which demonstrate MAPK
activation following viral infection, few have determined
whether this activation is important for a viral permissive in-
fection. The recent identification of dominant negative pro-
teins and chemical compounds which specifically inhibit differ-
ent MAPK kinases have allowed more detailed analysis of the
function of MAPK activation in virally infected cells (26, 27,
44). Using 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyri-
dyl) 1 H-imidazole (FHPI), a drug which inhibits p38 kinase
activity, investigators demonstrated that p38 kinase activity was
necessary for interleukin-1-mediated increased in human im-
munodeficiency virus replication (11), as measured by in-
creases in pp24 levels (27, 48). In another study, dominant
negative proteins were used to demonstrate that inhibition of
HSV-mediated JNK activation significantly decreases viral ti-
ters (34). However, even though p38 activation was observed
following HSV infection, FHPI had no effect on viral titers,
indicating that not all MAPKs which are activated following
infection have a critical role in viral permissive infection (T. I.
McLean and S. L. Bachenheimer, personal communication).
Even in cases where it has been determined that MAPK
activation has a function in viral infection, little is known about
how MAPK mediates this effect. For example, MAPK sub-
strates which are activated following viral infection have not
been identified. Furthermore, little is known about cellular
proteins that are involved in virus-mediated MAPK activation.
An understanding of these points is of great interest since it
will allow investigators to better examine the antiviral potential
of MAPKs, in addition to greatly increasing our knowledge of
how the virus regulates host cell machinery to ensure a per-
missive infection.
Interestingly, HCMV infection has been found to activate
both ERK1/2 and p38. In the absence of prestimulation,
ERK1/2 activation is observed at 5 to 15 min following viral
binding to the cell (3) and at 4 to 8 h postinfection (hpi)
following viral gene expression (46). Increased p38 activity is
detected at 8 hpi and maintained through 48 hpi (19).
Excitingly, treatment of infected cells with drugs which in-
hibit either ERK1/2 activation or p38 kinase activity signifi-
cantly delays viral DNA replication and subsequent plaque
formation (19; R. A. Johnson, A. D. Yurochko, S.-M. Huong,
and E.-S. Huang, unpublished data). Additional studies have
shown that inhibition of either p38 or ERK1/2 kinase activity
does not affect expression of the two viral major immediate-
early (IE) genes, IE1-72 and IE2-86 (19, 46). However, while
inhibition of ERK1/2 activation reduced expression of several
viral E genes necessary for initiation of viral DNA replication,
inhibition of p38 kinase activity did not, suggesting that rather
than having redundant roles, each has a distinct function in
HCMV infection (19, 48; Johnson et al., unpublished data).
As with other viruses, little is known about the mechanism of
p38 activation following HCMV infection or which cellular
proteins are phosphorylated in a p38-dependent manner fol-
lowing infection. Therefore, we have undertaken a detailed
study into the mechanism of p38 activation following HCMV
infection. Initially, we provide evidence that p38 is not acti-
vated immediately following viral binding to the host cell.
Rather, p38 is first activated at 8 to 10 hpi, and this activation
is maintained throughout infection (72 hpi), though a decrease
in activity is often detected at 24 hpi. Since extended activation
of p38 is unusual, we next examined whether any p38 sub-
strates were also activated for extended periods of time in a
p38-dependent manner. We present data suggesting that acti-
vation of p38 for extended periods of time is necessary for
HCMV-mediated hyperphosphorylation of pRb, which is ob-
served at 48 to 72 hpi, and for phosphorylation of heat shock
protein 27 (HSP27), which is observed from 12 to 48 hpi.
We then focused on the mechanism by which HCMV-me-
diated this unusually long-term activation of p38. We provide
evidence that HCMV utilizes two mechanisms to activate p38.
Our results suggest that at early times of infection, HCMV
inhibits dephosphorylation of activated p38, allowing an accu-
mulation of phosphorylated p38 in the absence of increased
MKK3/6 activity. At later times of infection (48 to 72 hpi),
increased activation of MKK3/6 allows continued p38 activa-
tion. To our knowledge, this is the first report of any stimulus
or virus which activates p38 by inhibiting dephosphorylation,
underscoring the complex interaction between HCMV and
infected host cells.
Collectively, the results of this study demonstrate that p38 is
activated for extended periods of time following infection, and
they also identify proteins phosphorylated in a p38-dependent
manner in the context of viral infection. Identifying these sub-
strates is significant since it will allow future investigation into
the biological function of p38 in HCMV infection. Finally,
several lines of evidence presented here suggest that HCMV
has developed multiple mechanisms to ensure activation of a
cellular kinase which is critical to initiation of viral DNA rep-
lication. Targeting these mechanisms may provide a means to
inhibit HCMV-mediated p38 activation and viral permissiveness.
MATERIALS AND METHODS
Cell culture and viral passage. Human embryonic lung (HEL) fibroblasts were
cultured in Eagle’s minimal essential media (EMEM) (Gibco, BRL) supple-
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mented with 10% fetal bovine serum (FBS) plus antibiotics. The human astro-
cytoma cell line U373MG was grown in Dulbecco’s modified Eagle medium
(DMEM) (Gibco, BRL) supplemented with 10% FBS plus antibiotics. Towne
strain HCMV (passages 36 to 40) was propagated in HEL fibroblasts as previ-
ously described (22).
Expression vectors and cell lines. FLAG-pCDNA3-MKK3 dominant negative
(MKK3dn) and FLAG-pCDNA3-MKK6 dominant negative (MKK6dn) expres-
sion vectors were kindly provided by Roger Davis and have been previously
described (44). To obtain cell lines, U373 cells were seeded in 35-mm-diameter
six-well plates at 106 cells/well. The following day they were transfected with the
indicated plasmid, using Fugene 6 as specified by the manufacturer (Boehringer
GmbH, Mannheim, Germany). Forty-eight hours later, fresh DMEM containing
10% FBS, antibiotics, and G418 (800 mg/ml) was added to each well. The
medium was changed every 5 days. After G418 selection, the expression of
transfected protein in U373 was confirmed by Western blot analysis, immuno-
precipitation, and immunofluorescence.
Antibodies and inhibitor drugs. All phosphospecific antibodies and the p38
nonphosphospecific antibody were purchased from New England Biolabs (NEB;
Beverly, Mass.). FLAG antibody M2 was obtained from Kodak (Rochester,
N.Y.). pRb antibody was from Santa Cruz Biotechnology (Santa Cruz, Calif.),
and cyclin D and cyclin E antibodies were from Oncogene Science (Cambridge,
Mass.). HSP27 antibody was from Sigma (St. Louis, Mo.). Anisomycin, rotenone,
and 2-deoxyglucose were purchased from Sigma. The specific p38 inhibitor drug
FHPI was purchased from Calbiochem (La Jolla, Calif.).
Western blot analysis. Fibroblasts were grown to confluence, serum starved
for 48 h, and then infected with HCMV at a multiplicity of infection (MOI) of 2
to 5 PFU per cell as described elsewhere (19). In experiments which utilized
FHPI, cells were pretreated with 10 mM FHPI for 1 h prior to infection. Fol-
lowing pretreatment, cells were infected and incubated in the presence of 10 mM
FHPI as previously described (19). At the indicated times, cells were harvested
in 23 Laemmli sodium dodecyl (SDS) sample buffer, boiled, and loaded onto
SDS-polyacrylamide gels. Mock-infected samples were treated and harvested in
the same manner as the infected samples, except that EMEM without virus was
used during the infection. Proteins were separated by polyacrylamide gel elec-
trophoresis (PAGE) and transferred overnight at 14 V to Immobilon-P transfer
membranes (Millipore, Bedford, Mass.). Blots were blocked for 30 min in 10%
(wt/vol) Carnation nonfat dry milk dissolved in phosphate-buffered saline (PBS)
with 0.1% Tween 20 (PBS1T). Blots were then probed with primary antibody
(1:1,000 dilution) for 2 h at room temperature or overnight at 4°C in PBS1T.
Blots were washed three times with PBS1T. After washing, the blots were
probed with secondary antibody (horseradish peroxidase-conjugated anti-mouse
or anti-rabbit immunoglobulin G [Sigma or NEB, respectively]). Blots were
washed in PBS1T and developed by enhanced chemiluminescence as specified
by the manufacturer (NEB).
Immunoprecipitations and kinase assays. Glutathione S-transferase (GST)–
c-Jun (amino acids [aa] 1 to 79) and GST–ATF-2 (full length) were purchased
from NEB. p38 and JNK kinase assays were performed as previously described
(43). Briefly, cells were pretreated and infected as described above. At the
indicated times, cells were harvested in lysis buffer (150 mM NaCl, 20 mM
Tris-HCl [pH 7.5], 1.0% Triton X-100, 0.5 mM EDTA, 50 mM NaF, 10%
glycerol, 20 mg of leupeptin per ml, 20 mg of phenylmethylsulfonyl fluoride
[PMSF] per ml, 1 mM sodium vanadate [Na3VO4]), rocked for 15 min at 4°C,
and then vortexed for 15 seconds. Cell debris was pelleted by centrifugation, and
the concentration of the supernatant was determined by the Bio-Rad protein
assay. For the JNK kinase assay, 75 mg of supernatant was rocked for 4 h at 4°C
with 1 mg of GST–c-Jun bound to GST beads (Biochem Pharmacia). For the p38
assay, p38 was immunoprecipitated overnight from 200 mg of supernatant in
ELB1 (0.25 M NaCl, 0.1% NP-40, 0.05 M HEPES [pH 7.0], 1 mM PMSF, 0.5
mM EDTA, 0.05 mM dithiothreitol [DTT]) plus 0.1 mM Na3VO4 with a p38
polyclonal antibody and 15 ml of protein G-Sepharose beads (Biochem Pharma-
cia). After the appropriate incubation, the beads were washed three times in lysis
buffer, and once in kinase buffer (20 mM HEPES [pH 7.5], 10 mM MgCl2, 50
mM NaCl2, 5 mM b-glycerophosphate, 1.5 mM EGTA, 1 mM PMSF, 0.5 mM
EDTA, 0.05 mM DTT, 0.1 mM Na3VO4). Kinase assays were then performed,
using 5 mCi of [g-32P]ATP/reaction and, in the case of p38, addition of 1 mg of
GST–ATF-2. After a 20-min incubation at 30°C, the beads were washed once and
then denatured with 23 SDS sample buffer. After boiling, the samples were
separated by SDS-PAGE on a 12% polyacrylamide gel, dried, and subjected to
autoradiography. Bands were quantitated with a densitometer.
Heat treatment and ATP depletion. Confluent, serum-starved cells were
washed once with EMEM which had been prewarmed to 45°C and then incu-
bated in EMEM at 45°C for 20 min. ATP depletion was performed as previously
described (35). Briefly, following infection or heat treatment, cells were washed
twice with PBS which was preheated to 37°C. Cells were then incubated with PBS
supplemented with 5 mM rotenone and 10 mM 2-deoxyglucose at 37°C for the
indicated times. Following the appropriated incubation, cells were washed twice
with PBS and harvested in 23 SDS lysis buffer.
In vivo analysis of HSP27 phosphorylation. Confluent, serum-starved fibro-
blasts were infected as described above. Three hours prior to harvesting, cells
were washed twice with phosphate-free EMEM prewarmed to 37°C and then
incubated with 0.4 mCi of [32P]orthophosphate per ml in phosphate-free EMEM
(ICN). Following a 3-h incubation, cells were harvested and protein concentra-
tion was determined by the Bio-Rad protein assay as described above. HSP27
was immunoprecipitated as described above and separated by SDS-PAGE on a
12% gel. HSP27 phosphorylation was then determined by autoradiography.
RESULTS
Kinetics of p38 activation following viral infection. Inhibi-
tion of p38 kinase activity by treatment of infected cells with
FHPI significantly inhibits HCMV DNA replication and de-
creases viral titers (19). Determining the mechanism of
HCMV-mediated p38 activation could identify new targets to
inhibit this activation and, therefore, viral permissiveness.
Since little is known about p38 activation following HCMV
infection, it was first necessary to determine the kinetics of p38
activation during HCMV infection. With this information, we
could focus our investigation of the mechanism of HCMV-
mediated p38 activation on those times which correlated with
increased levels of p38 activity.
To determine the kinetics of activation, an extended time
course was performed. Confluent fibroblasts were serum
starved for 48 h, infected with HCMV at an MOI of 2 to 5
PFU, and harvested at the indicated times postinfection. p38
activation was examined by Western blot analysis using a phos-
phospecific antibody which recognizes only the dually phos-
phorylated, and hence active, form of p38 (43). As shown in
Fig. 1A, HEL cells infected with HCMV did not display in-
creased p38 activity from 10 to 40 min following infection
(lanes 2 to 7). However, a strong increase in p38 phosphory-
lation was detected by 10 hpi (Fig. 1B, lane 4), which is con-
sistent with previously published reports (19). p38 phosphory-
lation decreased between 14 and 24 hpi, then increased
dramatically between 24 and 48 hpi, and remained at this level
through 72 hpi (Fig. 4B, lanes 5 to 9). Western blot analysis
using an antibody which recognizes both phosphorylated and
nonphosphorylated p38 demonstrated that the overall levels of
p38 protein were not significantly altered during the course of
infection, suggesting that the increase in phosphorylated p38
was not due to an elevation in the amount of p38 analyzed (Fig.
1B, lower blot).
To further characterize HCMV-mediated activation of p38,
fibroblasts were infected with unpurified virus stock which was
either untreated or UV irradiated prior to infection. UV irra-
diation creates thymidine dimers which prevents transcription
of viral genes without inhibiting the ability of the virus to bind
to and enter the host cell. As Fig. 1C shows, p38 activation was
observed only following infection with live virus, indicating that
viral protein synthesis is necessary for p38 activation following
HCMV infection. Similar results were obtained when fibro-
blasts were infected with sucrose gradient-purified live or UV-
irradiated virus (data not shown).
To verify that p38 phosphorylation correlated with p38 ki-
nase activity, a p38 kinase immunocomplex assay was per-
formed with GST–ATF-2 as a substrate. As shown in Fig. 2,
quantitation of band intensity demonstrates that p38 kinase
activity correlated well with p38 phosphorylation (compare
Fig. 1B with Fig. 2), in which activation was observed at early
times of infection, decreased at 24 hpi, and then rose again at
48 hpi. The drop in p38 activation at 24 hpi, which was found
in most, though not all, time courses, suggested that p38 acti-
vation may be biphasic.
The results in Fig. 1 and 2 demonstrate that p38 is activated
for an extended period of time following HCMV infection. It
is very unusual for stimuli to induce such a prolonged activa-
tion of p38, and the fact that HCMV does supports our hy-
pothesis that p38 activation has a very important role in
HCMV infection for extended periods of time.
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HCMV infection results in hyperphosphorylation of pRb
and phosphorylation of HSP27 in a p38-dependent manner.
The results in Fig. 1 and 2 suggest that p38 has a role in HCMV
infection throughout the course of infection. However, no one
has yet examined if the extended activation of p38 correlates
with activation of any p38 substrates in the context of viral
infection. For this reason, we sought to identify substrates
which are phosphorylated in a p38-dependent manner follow-
ing viral infection. Following activation by certain stimuli, p38
phosphorylates the pocket protein pRb and HSP27 (13, 47,
50). Furthermore, under specific conditions, increased p38 ki-
nase activity can regulate expression of the cell cycle-regulating
protein cyclin D (25).
We therefore examined whether under our conditions
HCMV infection can induce hyperphosphorylation of pRb and
whether inhibiting p38 kinase activity affected pRb phosphor-
ylation following infection. Fibroblasts were infected in the
presence or absence of FHPI, a drug that specifically inhibits of
p38 kinase activity and that we have previously used to exam-
ined the role of p38 in HCMV infection (19, 27). We then
examined by Western blot analysis the level of pRb hyperphos-
phorylation at various times following infection. As shown in
Fig. 3A, HCMV induced pRb hyperphosphorylation by 48 hpi
(lane 4). In the presence of FHPI, the amount of hyperphos-
phorylated pRb was significantly less (lane 5). This finding
indicates that p38 kinase activity effects pRb phosphorylation
following viral infection.
FIG. 1. Activation of p38 following HCMV infection. HEL fibroblasts were
infected with sucrose gradient-purified virus at an MOI of 2 to 5 PFU. Cells were
then harvested in 23 SDS sample buffer at the indicated time points, and
Western blot analysis using a p38 phosphospecific antibody was performed. (A)
Time course examining the effect of HCMV infection on p38 activation at times
corresponding to the first tier of activation of host cell transcription factors. (B)
(Top) Western blot demonstrating that p38 is phosphorylated on activating
residues beginning at 10 hpi; (bottom) Western blot using p38 antibody, which
recognizes all forms of p38, demonstrating that the overall levels of p38 do not
fluctuate. (C) Viral protein synthesis is necessary for HCMV-mediated p38
activation. Fibroblasts were infected with unpurified virus stock at an MOI of 2
to 5 PFU. Where indicated, virus was inactivated by UV irradiation prior to
infection. Blots were also probed for IE1-72 and IE2-86 gene expression to
demonstrate inactivation of virus by UV irradiation (UV-VIRUS). p.i., postin-
fection; (M), mock-infected cells; (I), infected cells; UV, UV-irradiated HEL
fibroblasts [positive control]); Phos., phosphorylated. The results are represen-
tative of five experiments.
FIG. 2. HCMV-induced p38 phosphorylation correlates with increases in p38
kinase activity. Fibroblasts were treated and infected as for Fig. 1. At the indi-
cated time points, cells were harvested in lysis buffer, and p38 kinase activity was
determined by using GST–ATF-2 (aa 1 to 254) as a substrate. Autoradiography
was analyzed with a densitometer, and the quantitation is shown. (M), mock
infected. The data are representative of two separate experiments.
FIG. 3. Inhibition of p38 kinase activity inhibits HCMV-mediated pRb hy-
perphosphorylation but does not effect HCMV mediated changes in cyclin E or
cyclin D protein levels. Fibroblasts were grown to confluence and then serum
starved for 48 h. Cells were pretreated for 1 h with 10 mM FHPI prior to infection
with HCMV. HCMV infection was done in the presence of FHPI, and extracts
were harvested at the indicated times. Western blot analysis was performed with
antibody for pRb (A), cyclin D (B), and cyclin E (C). M, mock infected; Phos.,
phosphorylated. Each experiment was performed at least three times, and rep-
resentative blots are shown.
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We next examined if treatment of FHPI altered cyclin D
and, as a control, cyclin E, protein levels in HCMV-infected
cells. HEL cells were infected in the presence or absence of
FHPI, and the levels of cyclin D and cyclin E proteins were
determined at the indicated times of infection by Western blot
analysis. As previously reported, we found that cyclin D levels
began to drop at 24 to 28 hpi (Fig. 3B, lanes 5 and 7) (5). As
was also previously demonstrated, cyclin E protein levels in-
creased slightly at 24 to 48 h (Fig. 3C, lanes 2 and 4) and then
decreased at 48 to 72 hpi (lanes 6 and 8) (5). In both cases,
FHPI had no effect on HCMV-mediated changes in protein
levels. This indicates that following HCMV infection, p38 ac-
tivity does not have a role in regulating cyclin D or cyclin E
protein levels.
Finally, we examined the ability of p38 to regulate phosphor-
ylation of HSP27 following viral infection. HEL cells were
infected in the presence or absence of FHPI and then labeled
with [32P]orthophosphate for 3 h prior to harvesting. HSP27
was immunoprecipitated from whole cell extract and separated
by SDS-PAGE, and the amount of phosphorylated HSP27 was
determined by autoradiography. As shown in Fig. 4, HSP27
was strongly phosphorylated at early (12 hpi) and late (48 hpi)
times of infection, and this increase in phosphorylation was
blocked by the presence of the p38 inhibitor compound FHPI
(Fig. 4; compare lanes 2 and 4 with lanes 3 and 5).
These data indicate that activated p38 regulates phosphor-
ylation of specific substrates throughout the course of infec-
tion. As discussed below, these results also identify biological
mechanism by which p38 may affect HCMV viral DNA repli-
cation.
HCMV infection does not activate MKK4 or JNK. The
above results confirm that p38 has an active role in phosphor-
ylating specific substrates for extended periods of time follow-
ing infection. Since extended activation of p38 is unusual, we
were interested in how HCMV was able to maintain p38 acti-
vation. This would further our understanding of the interaction
between HCMV and the host cell, with the long-term view of
identifying novel targets to inhibit HCMV-mediated p38 acti-
vation and, subsequently, viral permissive infection.
Following exposure to stimuli, increases in the level of phos-
phorylated p38 are due to increased phosphorylation or kinase
activity of MKK3/6 and/or MKK4 (reviewed in references 10
and 38). Based on this knowledge, we first examined if MKK4
was activated following infection. Again, we used a phos-
phospecific antibody, in this case one which recognizes only
phosphorylated, and hence activated, MKK4. Having deter-
mined the kinetics of p38 activation (Fig. 1), we could focus on
times of infection which corresponded to p38 activation. As
shown in Fig. 5A, HCMV infection did not activate MKK4
(lanes 2 to 6), while treatment of HEL fibroblasts with aniso-
mycin (a strong MKK4 activator) strongly induced MKK4
phosphorylation (lane 5).
To further demonstrate that MKK4 was not activated fol-
lowing HCMV infection, we examined the effect of HCMV
infection on activation of a second MKK4 substrate, JNK (9,
29, 38). A JNK kinase assay was performed with GST–c-Jun as
a substrate. Quantitation of band intensity (Fig. 5B) demon-
strates that JNK activity does not increase significantly follow-
ing HCMV infection. Together, these data indicate that MKK4
kinase activity is not increased during HCMV infection and
therefore cannot account for the increases in p38 activation.
MKK3 and MKK6 are activated at late times of HCMV
infection. Next, we determined if viral infection activated
MKK3 and MKK6, the remaining two cellular kinases which
FIG. 4. p38 kinase activity is necessary for phosphorylation of HSP27 follow-
ing viral infection. Confluent, serum-starved fibroblasts were infected and then
labeled with 0.4 mCi of [32P]orthophosphate per ml in the presence or absence
of FHPI 3 h prior to being harvested. At the indicated times, cell extracts were
harvested, and HSP27 was immunoprecipitated from 500 mg of whole-cell extract
per sample, separated by SDS-PAGE on a 12% gel, and subjected to autora-
diography. M, mock infected; Phos., phosphorylated.
FIG. 5. HCMV infection does not activate MKK4 or JNK. (A) Western blot
analysis of infected whole-cell extract with an antibody which recognizes only
active MKK4. For the positive control, HEL fibroblasts were treated with ani-
somycin (10 mg/ml) for 20 min and harvested in the same manner as the HCMV-
infected cells. (B) JNK is not activated following HCMV infection. Cells were
infected with HCMV and harvested in JNK lysis buffer, and JNK kinase activity
was determined with GST–c-Jun (aa 1 to 79) as a substrate. Following autora-
diography, band intensity was determined with a densitometer, and the quanti-
tated results are shown. UV-irradiated fibroblasts were used as a positive control.
(M), mock infected; Phos., phosphorylated. Each panel shows representative
data from at least three separate experiments.
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are known to phosphorylate p38 (10). Interestingly, while we
observed a strong increase in MKK3/6 phosphorylation at 48
and 72 hpi (Fig. 6A, lanes 5 and 6), only a very slight increase
in phosphorylation was observed at 12 hpi (lanes 2 and 3).
Again, Western blot analysis for b-actin demonstrated that
equal amounts of protein were loaded in each lane (Fig. 6B).
Thus, increased MKK3/6 activity accounts for p38 activation at
later times of infection (48 to 72 hpi). Since HCMV infection
results in the activation of p38 as early as 8 hpi, we postulated
that there must exist another mechanism to account for the
strong activation of p38 at the earlier time points.
Basal kinase activity of MKK3/6 is needed for p38 phos-
phorylation at early times of infection. In response to heat
shock, JNK is activated through inhibition of dephosphoryla-
tion rather than increased activity of upstream kinases (35).
This activation requires basal upstream kinase activity (in the
case of JNK, basal MKK4 activity is required) and inhibition of
dephosphorylation of activated JNK. We were interested in
determining whether HCMV activated p38 in a similar mech-
anism, since we were unable to detect an increase in MKK
activity at early times postinfection. To test this theory, it was
first necessary to demonstrate that basal activity of an MKK is
necessary for p38 activation following HCMV infection. Since
there are no drugs available to inhibit MKK3/6 kinase activity,
we made cell lines which expressed a nonphosphorylated
MKK6 or MKK3 (MKK3dn and MKK6dn). These are domi-
nant negative proteins which have their phosphorylation sites
mutated, and when overexpressed, they prevent the wild-type
protein from becoming phosphorylated (44).
Due to their low transfectability and ability to be passaged
only a limited number of times in tissue culture, HEL fibro-
blasts are unsuitable for making stable expressing cell lines by
transient transfection assay. Therefore, MKK3dn-, MKK6dn-,
and vector control (pCDNA3)-expressing cell lines were made
in the U373MG cells, which like fibroblasts are fully permissive
for HCMV infection in tissue culture. Importantly, the pattern
of p38 and MKK3/6 activation in U373MG cells following
HCMV infection mirrors that in infected fibroblasts (data not
shown). After transfection and subsequent selection, protein
expression in the cell lines was confirmed by immunofluores-
cence, immunoprecipitation, and Western blot analysis (Fig.
7A and data not shown). Following establishment of the cell
lines, the cells were infected, harvested, and analyzed for phos-
phorylation of p38 by Western blot analysis. As shown in Fig.
7B, expression of MKK6dn strongly inhibited the ability of
HCMV infection to induce p38 phosphorylation at 12 hpi
(compare lanes 4 and 6), while MKK3dn had a much less
significant effect on virus-mediated p38 activation (compare
lanes 4 and 5). This finding suggests that kinase activity of
MKK6 is necessary for HCMV to induce p38 phosphorylation
at early times of infection, even though only a slight increase in
MKK6 phosphorylation is observed at this time of infection
(Fig. 6).
HCMV inhibits dephosphorylation of p38 at early but not
late times of infection. The results in Fig. 7 suggest that p38 is
activated by the low levels of MKK6 basal kinase activity that
is present in unstimulated cells. For this basal kinase activity to
increase the steady-state level of phosphorylated p38, dephos-
phorylation of active p38 needs to be inhibited. This would
allow a buildup of activated p38. Therefore, the next step was
to determine the effect of HCMV infection on dephosphory-
lation of active p38. Traditional pulse-chase assays are not
sensitive enough for examining the inhibition of dephosphor-
ylation under these experimental conditions (35). Therefore,
to assess the effect of HCMV infection on dephosphorylation
of p38, it was necessary to inhibit the ability of upstream
kinases (such as MKK3 and MKK6) to phosphorylate p38 and
then monitor the rate of decline in the levels of phosphorylated
p38. To accomplish this task, we used the technique of ATP
FIG. 6. HCMV infection strongly activates MKK3/6 at later times of infec-
tion. (A) Fibroblast extract used in Fig. 5 were probed for MKK3/6 activation
using an MKK3/6 phosphospecific antibody. Band intensity was quantitated with
a densitometer. (B) Western blot analysis for b-actin demonstrates equal protein
loading in all samples. (M), mock infected; Phos., phosphorylated. The data
shown are representative of results from four separate experiments.
FIG. 7. Basal levels of MKK3/6 kinase activity are necessary and sufficient for
HCMV-mediated p38 activation. U373 cells were transfected with an expression
vector for either MKK3dn or MKK6dn. (A) After selection in medium containing
G418 (800 mg/ml), Western blot analysis using a FLAG monoclonal antibody was
performed to verify protein expression. (B) Cells were pretreated, infected, and
harvested as for Fig. 1. Western blot analysis was performed with polyclonal
phosphospecific (to demonstrate p38 activation) or nonphosphospecific (to dem-
onstrate that overall levels of p38 were equal) p38 antibodies. Phos., phosphor-
ylated. The data are representative of results from three separate experiments.
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depletion, which was successfully used by Meriin et al. to ex-
amine the rate of dephosphorylation of p38 and JNK following
various stress treatments (35). In this experiment, cells are
treated with the indicated stress. ATP is then depleted from
the cells, which inhibits upstream kinase activity. This prevents
the cell from further phosphorylating p38, and therefore the
rate of dephosphorylation is the sole determinant of the
level of phosphorylated p38. Following ATP depletion, time
points are taken, and the amount of phosphorylated protein
is determined by Western blot analysis with phosphospecific
antibodies. Meriine et al. also demonstrated that heat
shock-mediated p38 activation was not mediated through
inhibition of dephosphorylation (35). Therefore, we used
heat shock treatment as our control for the rate of dephos-
phorylation.
Cells were either infected for 12 h or heat shocked for 20
min and then subjected to ATP depletion. Cell extracts were
harvested at 0, 10, 15, and 20 min following addition of ATP-
depleting reagents. Subsequent Western blot analysis demon-
strated that the amount of phosphorylated p38 decreased sig-
nificantly in heat-shocked cells between 10 and 15 min after
addition of ATP-depleting reagents (Fig. 8A, compare lanes 7
and 8). This indicated that if phosphatase activity is not inhib-
ited, a decrease in the amount of phosphorylated p38 should
be observed between 10 and 15 min after addition of ATP-
depleting reagents. When cells infected for 12 h with HCMV
were subjected to ATP depletion, only a slight drop in the
amount of phosphorylated p38 was detected between 10 and 15
min after addition of ATP-depleting reagents (compare lanes
3 and 4). This indicates that HCMV infection is able to inhibit
dephosphorylation of active p38. To our knowledge, this is the
first report of p38 activation via inhibition of dephosphoryla-
tion of p38 by any stimulus.
We next examined whether dephosphorylation of activated
p38 was also inhibited at later times of infection, when phos-
phorylation of both p38 and MKK3/6 is observed. To answer
this question, ATP depletion was performed on cells which had
been infected for 48 h. As shown in Fig. 8B, following addition
of ATP-depleting reagents, dephosphorylation of activated p38
occurred extremely rapidly. No phosphorylated p38 could be
detected by 10 min after the start of ATP depletion. This
finding indicates that at 48 hpi, HCMV can no longer inhibit
dephosphorylation of active p38. Based on this observation, we
have developed a model in which HCMV utilizes two mecha-
nisms to ensure activation of p38 for extended periods of time
(Fig. 9). At early times of HCMV infection, dephosphorylation
of active p38 is inhibited, resulting in an accumulation of ac-
tivated p38 (Fig. 9A). In contrast, at later times of infection,
the ability of HCMV to inhibit p38 dephosphorylation is lost,
indicating another mechanism is responsible for p38 activation.
This mechanism is likely the significant increase in MKK3/6
activity that we observed at 48 to 72 hpi (Fig. 6 and 9B). It is
important to remember that in the ATP depletion experiment,
MKK3/6 cannot phosphorylate p38 (since no ATP is present),
and therefore MKK3/6 is unable to maintain phosphorylation
of p38. However, in the presence of ATP, the increased
MKK3/6 activity is sufficient to activate p38.
Again, the findings presented here underscore the impor-
tance of p38 activation in viral infection. The virus has devel-
oped two mechanisms to ensure activation of p38. These find-
FIG. 8. HCMV infection inhibits dephosphorylation of active p38 at early,
but not late, times of infection. (A) U373 cells were infected for 12 h or subjected
to heat shock (45°C for 20 min). ATP was depleted by the addition of rotenone
and 2-deoxyglucose, and cells were harvested at the indicated times after deple-
tion. The amount of phosphorylated p38 was determined by Western blot anal-
ysis. (B) Cells were infected for 48 h and then subjected to ATP depletion and
Western blot analysis as for panel A. Time 0, start of ATP depletion; M,
mock-infected cells; Phos., phosphorylated.
FIG. 9. Model for HCMV-mediated p38 activation. (A) At early times of infection, when no increase in MKK3/6 or MKK4 kinase activity is observed, the virus
prevents phosphatases from recognizing activated p38. As basal MKK3/6 kinase activity continues to phosphorylate p38, phosphatases are unable to dephosphorylate
p38, and so the amount of activated p38 accumulates. (B) At later times of infection, MKK3/6 kinase activity is increased, resulting in p38 activation.
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ings are exciting because the unusual mechanism of p38
activation at 12 hpi may provide an antiviral target which
inhibits HCMV-mediated p38 activation without affecting p38
activation in response to other stimuli.
DISCUSSION
In vivo, primary targets for HCMV lytic infection are termi-
nally differentiated cells in which many macromolecules and
cellular pathways, including kinase pathways such as p38,
which HCMV needs to undergo a lytic infection, are present at
low levels or are inactive (53). Several recent studies have
shown that HCMV infection elicits a mitogenic-like response
which results in activation of these critical cellular components
(see the introduction). However, little is known about the
mechanism by which HCMV induces this activation. In this
report, we have examined the kinetics and mechanisms of p38
activation following HCMV infection. In fibroblasts, viral pro-
tein expression is necessary to obtain p38 activation, which is
first observed at 8 to 10 hpi (Fig. 1 and 2). This is somewhat
surprising, since our laboratory recently reported that HCMV
infection of monocytes results in a dramatic up regulation of
p38 kinase activity by 15 min postinfection, independent of
viral protein expression (55). One explanation for these differ-
ences is that HCMV may utilize different receptors to bind
fibroblasts and monocytes. Alternatively, HCMV infection
may regulate p38 activation differently in permissive cell types
(such as fibroblasts) compared to nonpermissive cell types
(such as monocytes). Currently, we are trying to address this
issue by first identifying HCMV receptors on monocytes and
fibroblasts. In addition, we are comparing activation of p38
following HCMV infection of other permissive and nonper-
missive cell types.
We were also unable to detect p38 activation following in-
fection of unpurified viral stock in which HCMV had been
inactivated by UV irradiation prior to infection (Fig. 1C). This
suggests that secreted cytokines released by infected cells into
the media are not responsible for p38 activation in this case.
Based on these results, we believe it most likely that viral
proteins themselves are responsible for p38 activation through-
out the course of infection.
We then provide evidence that HCMV infection induces
hyperphosphorylation of pRb and HSP27 in a p38-dependent
manner. These results not only demonstrate that p38 is func-
tionally active throughout infection but also provide insight
into how p38 may mediate its biological effects on viral DNA
replication. pRb regulates expression of many cellular proteins
associated with DNA synthesis, and many of these proteins are
thought to be necessary for viral DNA replication (51). At
early stages of the cell cycle, pRb is hypophosphorylated, and
in this form it acts as an inhibitor of gene expression, in most
instances by directly complexing with transcription factors such
as E2F and suppressing their transactivation function (51).
Upon exposure to a proliferative signal, the cell induces hy-
perphosphorylation of pRb. Once hyperphosphorylated, pRb
loses its ability to suppress transactivation function, which re-
sults in transcription of the genes necessary for progression
into S phase and subsequent cellular DNA synthesis.
The classical binding partner for pRb is the E2F family of
transcription factors, and hyperphosphorylation of pRb is nec-
essary for relieving pRb-mediated suppression of E2F, which
results in cell cycle progression past the G1/S phase transition
point (reviewed in reference 39). However, the HCMV IE2-86
protein binds to pRb and alleviates pRb-mediated suppression
of E2F transactivation function (15). Furthermore, IE2-86 has
a high affinity for hypophosphorylated pRb, suggesting that
HCMV can induce E2F transactivation function in the absence
of pRb hyperphosphorylation (15). Therefore, while FHPI in-
hibits the pRb hyperphosphorylation observed following
HCMV infection, it is likely that it does not inhibit pRb-
mediated suppression of E2F transactivation function in the
context of viral infection. Indeed, our preliminary results indi-
cate this is the case (data not shown). However, pRb also
regulates the activity of several other proteins in a phosphory-
lation-dependent manner. As with E2F, these proteins, which
include histone deacetylases and RNA polymerase III, regu-
late expression of a variety of cellular genes involved in cell
cycle progression and likely have important functions in viral
infection (4, 24, 25, 32, 33). Currently, we are investigating the
role of these other proteins in viral infection.
HSP27 appears to have a critical role in protecting cells from
apoptosis following certain stresses (reviewed in references 8
and 14). One mechanism by which it does this is by acting as a
molecular chaperone. It binds to proteins and can either pre-
vent their incorrect folding or association with inhibitory pro-
teins and/or ensure their translocation between subcellular
compartments (14). In the context of viral infection, p38-me-
diated activation of HSP27 could have two functions. It might
serve to inhibit apoptosis following external stresses. This
would ensure that the virus is able to complete its life cycle
before the cell dies. Alternatively, infection itself is a type of
stress and may cause inactivation of proteins which are neces-
sary for viral permissiveness, due to either misfolding or incor-
rect compartmental localization. Therefore, HCMV may acti-
vate HSP27 to ensure that these proteins are active and able to
perform their function as it relates to HCMV-permissive in-
fection. As with the pRb hyperphosphorylation, we are cur-
rently addressing these possibilities.
The next series of experiments characterized the mechanism
of HCMV-mediated p38 activation. Using ATP depletion, we
provided evidence that at early times of infection, HCMV
inhibited dephosphorylation of activated p38, allowing an in-
crease in the steady-state levels of phosphorylated p38 in the
presence of only basal MKK6 kinase activity. We also consis-
tently detected an increase in the amount of active p38 imme-
diately following addition of ATP-depleting reagents but be-
fore ATP had been depleted from the cells (Fig. 8, compare
lanes 2 and 3). This increase was not due to the process of ATP
depletion, as no increase in the amount of phosphorylated p38
was detected following addition of ATP-depleting reagents to
either heat-shocked cells or cells infected with HCMV for 48 h.
Little is known about the mechanism which mediates activa-
tion of p38 or JNK by inhibition of dephosphorylation, and
therefore it is difficult to speculate on why this increase occurs.
It may be due to the efficient use of residual ATP by HCMV-
infected cells before the ATP depletion is complete. Alterna-
tively, it may be a characteristic of stimuli which activates p38
or JNK by inhibition of dephosphorylation. We are currently
addressing these questions experimentally.
While inhibition of dephosphorylation is an uncommon
mechanism for inducing MAPK activation, a similar mecha-
nism was recently found for heat shock-mediated activation of
JNK (35). In that study, basal MKK4 kinase activity coupled
with inhibition of JNK dephosphorylation was sufficient to
induce JNK activation. Two other reports have been published,
both examining activation of ERK1/2 by inhibition of dephos-
phorylation. The first report described inhibition of protein
phosphatase PP2A activity by SV40 small T antigen (41). This
inhibition allowed accumulation of phosphorylated MKK1/2
and ERK in the absence of increased MKKK activity (54). A
second report demonstrated that activation of ERK1/2 follow-
ing HCMV infection of prestimulated fibroblasts may be at
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least partially due to inhibition of ERK1/2 dephosphorylation
(46).
It may be fortuitous for HCMV to use an unusual mecha-
nism to activate p38. For instance, increased MKK6 kinase
activity has been implicated in some types of apoptosis (18). By
not increasing MKK6 kinase activity, HCMV may avoid this
effect, which would be detrimental to a successful viral life
cycle. Also, many stimuli that activate p38 by activation of
upstream kinases also activate JNK. Recently, it has been sug-
gested that the antiviral property of tumor necrosis factor
alpha may be due to its ability to activate JNK (1). By activat-
ing p38 through inhibition of dephosphorylation rather than
increasing kinase activity of MKKs, perhaps HCMV ensures
that JNK is not activated. This theory is supported by our
findings that neither MKK4 nor JNK is activated following
infection (Fig. 5).
HCMV could inhibit dephosphorylation of activated p38 by
two mechanisms. It could directly bind to and inactivate one or
more p38-specific phosphatases. This would be analogous to
SV40 small T antigen, which binds to a subunit of the PP2A
complex, preventing the formation of an active PP2A (41, 54).
Alternatively, it could somehow prevent active phosphatases
from recognizing p38, perhaps by binding p38 in such a way
that it is masked from the phosphatases. We have found that
p38 phosphatases are strongly activated following infection
(data not shown), which correlates with previously published
data showing that PP2A and PP1, both of which can dephos-
phorylate p38, are activated following HCMV infection (36).
These findings suggest that p38 is likely activated by the latter
mechanism (activated phosphatases cannot recognize phos-
phorylated p38) following HCMV infection.
Currently, we are addressing the question of which viral
proteins are responsible for the inhibition of dephosphoryla-
tion. One problem with identifying these candidates is that it is
difficult to determine the exact time at which the infected cell
begins accumulating phosphorylated p38. The earliest we have
been able to detect p38 phosphorylation is 6 to 8 hpi. However,
since activation depends on basal kinase activity, it may be
quite some time between the commencement of inhibition of
p38 dephosphorylation and the detection of p38 activation. We
have looked for the ability of the two major viral IE proteins
(IE1-72 and IE2-86) to activate p38 but have been unable to
induce p38 activation by overexpression of either IE2-86 or
IE1-72 (data not shown). Aside from the possibility that these
proteins may not be involved in p38 activation, two alternate
explanations for why we have been unable to detect p38 acti-
vation by specific viral proteins are that posttranslational mod-
ification of IE proteins, such as phosphorylation, and/or ex-
pression of multiple viral genes is necessary to obtain p38
activation. Our search has been further complicated by the fact
that different mechanisms are utilized to activate p38 at early
and late times of infection. Currently, we are developing better
techniques to identify the viral proteins necessary for p38 ac-
tivation.
We went on to show that at later times of infection, HCMV
no longer inhibited dephosphorylation of activated p38 (Fig.
8B). However, MKK3/6 activity was increased at these later
times of infection (Fig. 6), and this increased activity was suf-
ficient to increase the steady-state level of activated p38. This
finding indicates HCMV utilized a different mechanism to
activate p38 at later times of infection. These results may also
explain why a decrease in p38 phosphorylation was often ob-
served at 24 hpi. The ability of HCMV to inhibit dephosphor-
ylation of p38 may be lost before MKK3/6 is activated. At that
time of infection, no mechanism to activate p38 would be
present, and the levels of phosphorylated p38 would drop.
This characterization of HCMV-mediated p38 activation
provides important new insight into the complex interaction
between HCMV and the infected host cell. We have demon-
strated that p38 is activated during viral infection. We have
also identified two p38 substrates which are phosphorylated in
a p38-dependent manner in the context of a viral infection,
which will be helpful in future studies of the biology of p38
function in the context of viral infection. Finally, this study
provides strong evidence that HCMV activates p38 by two
different mechanisms, including the very unusual mechanism
of inhibition of dephosphorylation. Since it is unusual, it may
provide a future target for preventing p38 activation and, sub-
sequently, HCMV infection.
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